WeVote
Log In

Bill

Bill

HB 2367

Pharmacogenomics pilot program; established, report.

2025 Regular Session Introduced by Geary Higgins and 1 co-sponsor

Virginia establishes a pharmacogenomics pilot program to test genetic-based medication personalization and report findings to improve drug treatment outcomes.

Left in Health and Human Services
0
WeVote Research Nonpartisan
Bill Summary · HB 2367

Legislative bill overview

HB 2367 establishes a pharmacogenomics pilot program in Virginia that would test personalized medication approaches based on individual genetic profiles. The bill requires the development and implementation of this pilot program, along with a comprehensive report on its findings and recommendations.

Why is this important

Pharmacogenomics—tailoring medications to a patient's genetic makeup—can reduce adverse drug reactions, improve treatment efficacy, and potentially lower healthcare costs. A pilot program could provide Virginia with data on whether implementing such testing statewide is feasible, cost-effective, and clinically beneficial for residents.

Potential points of contention

  • Cost and funding: No clear indication of who funds the pilot or how expenses are allocated between state agencies, healthcare systems, and insurers
  • Access and equity: Unclear whether the pilot would be available to all Virginians or limited populations, potentially raising concerns about healthcare disparities
  • Implementation timeline: The bill's current status (recommended for laying on the table) suggests legislative uncertainty about prioritization or readiness to move forward

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.